# Correction and utilization of the washout effect in range-verification PET for particle therapy

**Authors:** Chie Toramatsu, Iwao Kanno, Taiga Yamaya

PMC · DOI: 10.1007/s12194-025-01000-2 · Radiological Physics and Technology · 2026-01-05

## TL;DR

This paper reviews how the biological washout effect impacts PET imaging in particle therapy and discusses ways to correct and use it for better treatment verification and tumor evaluation.

## Contribution

The paper provides a comprehensive review of the biological washout effect's correction and potential utilization in particle therapy PET.

## Key findings

- The biological washout effect is a tissue-specific phenomenon affecting PET-based range verification.
- Correction methods for the washout effect are essential for accurate beam range verification.
- The washout effect may provide insights into tumor vascular status and cancer pathophysiology.

## Abstract

In charged particle therapy, it is essential to verify the irradiation beam range. Thus, using positron (β+)-emitting nuclides which are produced in irradiated tissue, positron emission tomography (PET) has been studied, and clinically applied for in vivo range verification in particle therapy. However, a correction method for the biological washout effect is one of the fundamental issues for quantitative verification of the beam range; the irradiation-induced β+-emitting nuclides are affected by the pathophysiological environment such as blood perfusion. Since the biological washout effect is a tissue-specific phenomenon, extensive basic and clinical research has been conducted for modeling its kinetic process. Although considered as an undesirable factor in PET-based range validation, on the other hand, the biological washout effect may provide unique insights into the vascular status of a tumor and potentially support evaluation of the cancer pathophysiology. Consequently, this review provides a comprehensive outline of studies of the biological washout effect in particle therapy, focusing on both its correction and potential beneficial utilization.

## Full-text entities

- **Diseases:** hypoxic (MESH:D002534), chordoma (MESH:D002817), hypoxia (MESH:D000860), ocular melanoma (MESH:D008545), glioma (MESH:D005910), liver, lung, prostate, and brain cancers (MESH:D011471), osteosarcoma (MESH:D012516), H&amp;N tumors (MESH:D009369), ischemic (MESH:D002545), necrotic (MESH:D009336), liver cancer (MESH:D006528), H&amp;N (MESH:D000848), brain tumor (MESH:D001932), chondrosarcoma of the skull base (MESH:D019292), vascular damage (MESH:D057772)
- **Chemicals:** H2O (MESH:D014867), 15O (MESH:C000615263), oxygen (MESH:D010100), HCOOH (MESH:C030544), CO (MESH:D002248), Carbon (MESH:D002244), CO2 (MESH:D002245), Gd (MESH:D005682), 11C (MESH:C000615233), 11C-methionine (MESH:C086242), 10C (-), proton (MESH:D011522), FDG (MESH:D019788)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Canis lupus familiaris (dog, subspecies) [taxon 9615], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C6 glioma cancer — Rattus norvegicus (Rat), Rat malignant glioma, Cancer cell line (CVCL_3581)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950064/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950064/full.md

---
Source: https://tomesphere.com/paper/PMC12950064